|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
ATE68703T1
(de)
|
1984-02-08 |
1991-11-15 |
Cetus Corp |
Toxinkonjugate.
|
|
GB8422238D0
(en)
|
1984-09-03 |
1984-10-10 |
Neuberger M S |
Chimeric proteins
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4815397A
(en)
*
|
1986-07-28 |
1989-03-28 |
Warren Engineering Corporation |
Sludge treatment apparatus
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
EP0307434B2
(en)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Altered antibodies
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
AU8507191A
(en)
|
1990-08-29 |
1992-03-30 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US6797492B2
(en)
|
1991-05-17 |
2004-09-28 |
Merck & Co., Inc. |
Method for reducing the immunogenicity of antibody variable domains
|
|
ATE255131T1
(de)
|
1991-06-14 |
2003-12-15 |
Genentech Inc |
Humanisierter heregulin antikörper
|
|
CA2111006C
(en)
|
1991-06-21 |
2008-04-08 |
Andrew D. Boyd |
A novel receptor-type tyrosine kinase and use thereof
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
DE69233528T2
(de)
|
1991-11-25 |
2006-03-16 |
Enzon, Inc. |
Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
|
|
US6027725A
(en)
|
1991-11-25 |
2000-02-22 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US6331302B1
(en)
|
1992-01-22 |
2001-12-18 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
|
CA2128722A1
(en)
|
1992-01-22 |
1993-08-05 |
William I. Wood |
Novel protein tyrosine kinases
|
|
US5635177A
(en)
|
1992-01-22 |
1997-06-03 |
Genentech, Inc. |
Protein tyrosine kinase agonist antibodies
|
|
DK1975181T3
(da)
|
1992-10-28 |
2011-06-06 |
Genentech Inc |
Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
|
|
US5824303A
(en)
|
1992-11-13 |
1998-10-20 |
Amgen Inc. |
Eck receptor ligands
|
|
AU685765B2
(en)
|
1992-11-13 |
1998-01-29 |
Amgen, Inc. |
(Eck) receptor ligands
|
|
US5512591A
(en)
|
1993-02-18 |
1996-04-30 |
President And Fellows Of Harvard College |
Treatments for diseases characterized by neovascularization
|
|
ES2152753B1
(es)
|
1993-03-29 |
2001-09-01 |
Ct Investig Energeticas Ciemat |
Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
|
|
US5698413A
(en)
|
1993-05-05 |
1997-12-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Method of evaluating chemotherapeutic agents in vivo
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
JPH08511420A
(ja)
|
1993-06-16 |
1996-12-03 |
セルテック・セラピューテイクス・リミテッド |
抗 体
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5624899A
(en)
|
1994-07-20 |
1997-04-29 |
Genentech Inc. |
Method for using Htk ligand
|
|
AU3144195A
(en)
|
1994-07-26 |
1996-02-22 |
Rutgers, The State University Of New Jersey |
Human brain specific kinase
|
|
US5795734A
(en)
|
1994-09-19 |
1998-08-18 |
President And Fellows Of Harvard College |
EPH receptor ligands, and uses related thereto
|
|
WO1996013518A1
(en)
|
1994-10-27 |
1996-05-09 |
Genentech, Inc. |
Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
WO1996026958A2
(en)
|
1995-02-27 |
1996-09-06 |
President And Fellows Of Harvard College |
Eph RECEPTOR LIGAND ELF-2
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
ES2202469T5
(es)
|
1995-09-08 |
2011-06-06 |
Genentech, Inc. |
Proteína relacionada con el vegf.
|
|
US5837534A
(en)
|
1995-11-14 |
1998-11-17 |
The Board Of Regents Of The University Of Texas System |
Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
|
|
AUPN727795A0
(en)
|
1995-12-22 |
1996-01-18 |
Walter And Eliza Hall Institute Of Medical Research, The |
A novel receptor-type tyrosine kinase and use thereof
|
|
US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
|
US6413730B1
(en)
|
1996-07-05 |
2002-07-02 |
Mount Sinai Hospital Corporation |
Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
|
|
UA73073C2
(uk)
|
1997-04-03 |
2005-06-15 |
Уайт Холдінгз Корпорейшн |
Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
|
|
IL132240A0
(en)
|
1997-04-07 |
2001-03-19 |
Genentech Inc |
Anti-vegf antibodies
|
|
WO1998045708A1
(en)
|
1997-04-08 |
1998-10-15 |
Sugen, Inc. |
Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
|
|
US6440954B1
(en)
|
1997-04-18 |
2002-08-27 |
President And Fellows Of Harvard College |
Inhibition of vascular smooth muscle cell proliferation
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
WO1998052976A1
(en)
*
|
1997-05-21 |
1998-11-26 |
Biovation Limited |
Method for the production of non-immunogenic proteins
|
|
JP3417803B2
(ja)
*
|
1997-07-07 |
2003-06-16 |
リンテック株式会社 |
ハードコートシート
|
|
WO1999008696A1
(en)
|
1997-08-19 |
1999-02-25 |
Vanderbilt University |
METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
|
|
EP1019080A2
(en)
|
1997-10-02 |
2000-07-19 |
Leukosite, Inc. |
Modulation of lerk-2-mediated cell adhesion
|
|
IL138608A0
(en)
|
1998-04-02 |
2001-10-31 |
Genentech Inc |
Antibody variants and fragments thereof
|
|
US6864227B1
(en)
|
1998-04-13 |
2005-03-08 |
California Institute Of Technology |
Artery-and vein-specific proteins and uses therefor
|
|
US6887674B1
(en)
|
1998-04-13 |
2005-05-03 |
California Institute Of Technology |
Artery- and vein-specific proteins and uses therefor
|
|
AU8788998A
(en)
|
1998-10-02 |
2000-04-06 |
Universite Paris 7 |
Vascular specific regulatory elements contained in the desmin 5' flanking region
|
|
AUPP674898A0
(en)
|
1998-10-27 |
1998-11-19 |
Walter And Eliza Hall Institute Of Medical Research, The |
A method of treatment
|
|
ATE293989T1
(de)
|
1998-11-20 |
2005-05-15 |
Genentech Inc |
Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
|
|
EP1051432B1
(en)
|
1998-12-08 |
2007-01-24 |
Biovation Limited |
Method for reducing immunogenicity of proteins
|
|
WO2002011785A2
(en)
|
2000-08-03 |
2002-02-14 |
The University Of Utah Research Foundation |
Manipulation of arterial-venous identity
|
|
WO2002026827A1
(en)
|
2000-09-29 |
2002-04-04 |
Novartis Ag |
Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
|
|
CA2429460A1
(en)
|
2000-11-20 |
2002-05-23 |
California Institute Of Technology |
Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US6958140B2
(en)
|
2001-01-26 |
2005-10-25 |
Regeneron Pharmaceuticals, Inc. |
Methods of imaging and targeting vasculature
|
|
EP1358211A2
(en)
|
2001-01-31 |
2003-11-05 |
Mount Sinai Hospital |
Methods for regulating the kinase domain of ephb2
|
|
WO2002079382A2
(en)
|
2001-03-30 |
2002-10-10 |
President And Fellows Of Harvard College |
B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
CN1531554A
(zh)
*
|
2001-06-26 |
2004-09-22 |
��������ҽѧ����˾ |
血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体
|
|
US7321026B2
(en)
|
2001-06-27 |
2008-01-22 |
Skytech Technology Limited |
Framework-patched immunoglobulins
|
|
CA2452578A1
(en)
|
2001-07-03 |
2003-01-16 |
The Hospital For Sick Children |
Ephrin and eph receptor mediated immune modulation
|
|
IL159422A0
(en)
*
|
2001-09-20 |
2004-06-01 |
Cornell Res Foundation Inc |
Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate-specific membrane antigen
|
|
US6619055B1
(en)
*
|
2002-03-20 |
2003-09-16 |
Honeywell International Inc. |
Security system with wireless thermostat and method of operation thereof
|
|
EP1575509B1
(en)
|
2002-05-10 |
2011-10-26 |
Purdue Research Foundation |
Epha2 agonistic monoclonal antibodies and methods of use thereof
|
|
ATE525398T1
(de)
|
2002-05-10 |
2011-10-15 |
Medimmune Inc |
Epha2 monoklonale antikörper und deren anwendungsverfahren
|
|
US20040110150A1
(en)
|
2002-12-10 |
2004-06-10 |
Isis Pharmaceuticals Inc. |
Modulation of Ephrin-B2 expression
|
|
JP2004053694A
(ja)
|
2002-07-16 |
2004-02-19 |
Sharp Corp |
表示装置、文字・図形表示制御方法、文字・図形表示プログラムおよび可読記録媒体
|
|
US20040023420A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Macromix International Co., Ltd. |
Method for reduced photoresist usage
|
|
AU2002951409A0
(en)
|
2002-09-16 |
2002-09-26 |
North Western Adelaide Health Services |
Methods for regulating cancer
|
|
EP1606305A4
(en)
|
2003-03-12 |
2009-06-24 |
Vasgene Therapeutics Inc |
NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
|
|
US7381410B2
(en)
*
|
2003-03-12 |
2008-06-03 |
Vasgene Therapeutics, Inc. |
Polypeptide compounds for inhibiting angiogenesis and tumor growth
|
|
WO2004091375A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Epha2 and non-neoplastic hyperproliferative cell disorders
|
|
DE10325166B4
(de)
*
|
2003-06-04 |
2006-11-23 |
Graf von der Schulenburg-Wolfsburg, Günzel, Dr. |
Gleisaufbau für schienengebundene Fahrzeuge, insbesondere Eisenbahnen
|
|
WO2005048917A2
(en)
|
2003-06-06 |
2005-06-02 |
Medimmune, Inc. |
Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
|
|
CN1905899B
(zh)
|
2003-11-20 |
2011-09-28 |
医学免疫公司 |
EphA2激动性单克隆抗体及其使用方法
|
|
EP2275445A3
(en)
|
2004-03-12 |
2012-02-29 |
Vasgene Therapeutics, Inc. |
Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth
|
|
EP1619521A1
(en)
|
2004-07-22 |
2006-01-25 |
IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. |
Capacitive transmitter electrode
|
|
WO2006047639A2
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Inc. |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
|
EP2388271A3
(en)
|
2005-02-03 |
2012-08-01 |
Antitope Limited |
Human Antibodies and Proteins
|
|
EP1973950B1
(en)
*
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
|
WO2008042941A2
(en)
|
2006-10-04 |
2008-04-10 |
Medimmune, Llc |
Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
|
|
EP2137216A2
(en)
|
2007-03-12 |
2009-12-30 |
Vasgene Therapeutics, Inc. |
Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
|